Correction to: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution

Florou, Vaia; Rosenberg, Andrew E.; Wieder, Eric; Komanduri, Krishna V.; Kolonias, Despina; Uduman, Mohamed; Castle, John C.; Buell, Jennifer; Trent, Jonathan C.; Wilky, Breelyn A.

doi:10.1186/s40425-019-0792-9

Cited by 9 publications

(4 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Continued work to identify mutations specific to breast angiosarcoma can help to drive novel treatments that may facilitate improved patient outcomes [31]. Additionally, our group has identified actionable mutations, evaluated tumor mutational burden, and is assessing the efficacy of checkpoint inhibition [32,33]. This work lays the foundation for targeted therapy to tailor treatments for PAS and RAAS patients in the curative setting.…”

Section: Discussionmentioning

confidence: 99%

Clinical Outcomes for Primary and Radiation-Associated Angiosarcoma of the Breast with Multimodal Treatment: Long-Term Survival Is Achievable

Kronenfeld

Crystal

Ryon

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

Background: The optimal management of primary angiosarcoma (PAS) and radiation-associated angiosarcoma (RAAS) of the breast remains undefined. Available data show persistently poor survival outcomes following treatment with surgery or chemotherapy alone. The objective of this study was to evaluate long-term outcomes in patients treated with multimodality therapy. Methods: Patients diagnosed with stage I–III PAS or RAAS of the breast were identified from our local tumor registry (2010–2020). Patient demographics, tumor characteristics, and treatment were collected. Primary outcomes were local recurrence (LR), distant recurrence (DR), and median overall survival (OS). A secondary outcome was pathologic complete response (pCR) following neoadjuvant chemotherapy (NAC). Mann–Whitney U, chi-squared, or Fisher exact tests were used to analyze data. Kaplan–Meier curves compared OS for PAS and RAAS. Results: Twenty-two patients met inclusion criteria, including 11 (50%) with RAAS and 11 (50%) with PAS. Compared to PAS patients, RAAS patients were older and had more comorbidities. For RAAS patients, median time from radiation to diagnosis was 6 years (IQR: 5–11). RAAS patients were more likely to have a pCR to NAC (40% vs. 20%, p = 0.72). RAAS patients had a higher LR rate (43% vs. 38%, p = 0.83), and PAS patients were more likely to develop a DR (38% vs. 0%, p = 0.07). Median OS was 81 months in PAS patients and 90 months in RAAS patients (p = 1.00). Discussion: Long-term survival can be achieved in patients with PAS and RAAS who undergo multimodality treatment. NAC can result in pCR. The long-term clinical implications of pCR warrant further investigation.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical Outcomes for Primary and Radiation-Associated Angiosarcoma of the Breast with Multimodal Treatment: Long-Term Survival Is Achievable

Kronenfeld

Crystal

Ryon

et al. 2021

Cancers

Self Cite

View full text Add to dashboard Cite

show abstract

“…A twosided p-value < 0.05 was considered statistically significant. Statistical analyses were performed using SPSS 28.0 and SAS 9.4. patients had received a median RT dose for the IT of 57 Gy (45-66), in a median of 30 fractions (23)(24)(25)(26)(27)(28)(29)(30)(31)(32)(33). Roughly 62% developed OST in the head and neck (n = 10) (p ⩽ 0.001), and most had high-grade tumours (93%, n = 13/14).…”

Section: Discussionmentioning

confidence: 99%

“… 24 Clinical activity of ICI in RIS has been illustrated in the publication of Florou et al ., where the authors reported a case of metastatic RIS BAS that achieved sustained PR on pembrolizumab following disease progression upon anthracycline-based chemotherapy, gemcitabine/docetaxel and pazopanib. 25 It is reasonable to believe that comparative analyses of genomic and tumour immune infiltrate profiles may be helpful to elucidate not only to what extent certain RIS histologies differ from their non-radiation-induced counterparts but also if similar immunotherapy responses can be expected, especially in specific sarcoma subtypes for which preliminary encouraging activity has been suggested (e.g. UPS, angiosarcoma, liposarcoma).…”

Section: Discussionmentioning

confidence: 99%

Clinico-demographic characteristics and outcomes of radiation-induced sarcomas (RIS): a CanSaRCC study

Ribeiro,

Peretz Soroka,

Bhura

et al. 2023

Ther Adv Med Oncol

View full text Add to dashboard Cite

Background: Radiation-induced sarcomas (RIS) tend to have aggressive behaviour and because of their rarity, the most appropriate management for these malignancies is uncertain. Objectives: Using the Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) database, a national sarcoma registry, we aimed to investigate prognostic factors and outcomes for RIS. Design: Retrospective study of RIS patients treated from 1996 to 2021 at three Canadian centres. Methods: RIS was defined as a sarcoma arising in a previously irradiated field following a 3+ year latency period, whose histology was distinct from the initially irradiated tumour. Clinicopathologic and treatment-related information was extracted from the CanSaRCC database. Overall survival (OS) was defined as the time from RIS diagnosis to death from any cause. Response rate (RR) to neoadjuvant chemotherapy (NACT) was based on physician assessment. Time-to-event analyses were estimated using the Kaplan–Meier method, with Cox regression for multivariate analysis. We considered a two-tailed p-value of <0.05 as statistically significant. Results: One hundred seven tumours met the criteria for RIS and were divided into three subgroups: breast angiosarcoma (BAS, n = 54), osteosarcoma (OST, n = 16), and other soft-tissue sarcomas (STS, n = 37). Patients were mostly female ( n = 85, 79%), treated initially for breast carcinomas ( n = 54, 50.5%), and diagnosed with high-grade tumours ( n = 61/71, 86%). None had evidence of synchronous metastasis. Patients with OST were younger (median age: 48 years, p < 0.001), and BAS had the shortest latency interval (8 versus 18 years for OST/STS, p < 0.001). Most patients underwent surgery, 76% ( n = 76/100) R0; 24% ( n = 26) received radiation therapy, mostly ( n = 15, 57.7%) neoadjuvant. Among those receiving chemotherapy, 30 (75%) underwent NACT; among patients with documented response assessment, the RR was 68% ( n = 17/25), being even higher in the BAS population (89.5%, n = 13/17). Median OS was 53 months (95% CI 34–101), with a 5-year OS of 47.6%; larger tumour size, high histologic grade and older age were independent prognostic factors for worse OS. Conclusion: Surgery is standard, and NACT might be useful to downsize large lesions, especially in BAS patients. Raising RIS awareness is fundamental to promoting appropriate management and fostering research through multi-institutional collaborations.

show abstract

“…The other effective chemotherapy regimens include doxorubicin/ifosfamide/mesna ( 10 ), adriamycin/ifosfamide ( 29 ), cyclophosphamide/gemcitabine/docetaxel ( 30 ) and docetaxel/cisplatin ( 16 ). Previous studies reported that immunotherapy is effective against angiosarcoma ( 31 , 32 ). Radiotherapy and immunotherapy with recombinant interleukin-2 (rIL-2) was also reported to be effective ( 33 ).…”

Section: Discussionmentioning

confidence: 99%

Primary pulmonary epithelioid angiosarcoma with thyroid tumor history: A case report and literature review

et al. 2022

View full text Add to dashboard Cite

Primary pulmonary epithelioid angiosarcoma is a rare tumor type without any specific clinical and imaging features. Therefore, it is associated with high rates of misdiagnosis. The present study reports the case of a 54-year-old female patient who was admitted after complaining of cough, expectoration and bloody sputum for >5 months in May 2021. The patient reported a previous history of papillary thyroid carcinoma in 2003 and had undergone treatment through surgery, postoperative chemotherapy and iodine 131 therapy. Chest computed tomography (CT) was performed in May 2021, which indicated that the disease had progressed rapidly since February 2021. CT-guided lung biopsy and immunohistochemical staining of the tumor indicated positivity for CD31, CD34 and E26 transformation-specific-related gene markers. The tumor was negative for thyroid cancer-associated antibodies; thus, a diagnosis of primary pulmonary epithelioid angiosarcoma was made. The patient died 3 months after the diagnosis. Primary pulmonary epithelioid angiosarcoma is a rare tumor type with high recurrence and metastasis rates. This tumor has no specific clinical symptoms and signs and is thus easily misdiagnosed. Biopsy is essential for diagnosis of the disease, particularly if patients have a tumor history.

show abstract

Correction to: Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution

Cited by 9 publications

References 1 publication

Clinical Outcomes for Primary and Radiation-Associated Angiosarcoma of the Breast with Multimodal Treatment: Long-Term Survival Is Achievable

Clinical Outcomes for Primary and Radiation-Associated Angiosarcoma of the Breast with Multimodal Treatment: Long-Term Survival Is Achievable

Clinico-demographic characteristics and outcomes of radiation-induced sarcomas (RIS): a CanSaRCC study

Primary pulmonary epithelioid angiosarcoma with thyroid tumor history: A case report and literature review

Contact Info

Product

Resources

About